xRead - September 2022

Wise et al.

Page 434

Author Manuscript Author Manuscript Author Manuscript Author Manuscript TABLE X.A.4-4. Study

Omalizumab: reduced asthma exacerbations; increased AQLQ and RQLQ; reduced asthma symptoms; increased FEV1, FVC, and PEF. No difference in β -agonist use.

design Study groups Clinical endpoint Conclusion

Omalizumab addition to SCIT: reduced symptom severity, improved QOL by ACQ and AQLQ. No difference in rescue medication use. No difference in FEV1 or mean PEF.

AR and asthma symptoms, rescue medication use, PEF, patient and provider GETE, asthma symptoms by ACQ, disease-specific QOL by AQLQ and RQLQ, PFTs

Asthma exacerbations, disease-specific QOL by AQLQ and RQLQ, rescue medication use, symptom scores, patient and investigator

GETE, inhaled corticosteroid use, FEV1, FVC, and morning PEF

1 SCIT + omalizumab; 2 SCIT + placebo

1 Omalizumab; 2 Placebo

SCIT. (n = 140):

asthma (n = 405):

Evidence for omalizumab for the treatment of asthma in the context of coexistent allergic rhinitis Study Year LOE Kopp et al. 1403 2009 1b DBRCT AR and seasonal asthma. All patients received Vignola et al. 1820 2004 1b DBRCT Moderate-to-severe persistent AR and allergic

ACQ = Asthma Control Questionnaire; AQLQ = Asthma Quality of Life Questionnaire; AR = allergic rhinitis; DBRCT = double-blind randomized controlled trial; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; GETE = Global Evaluation of Treatment Effectiveness; LOE = level of evidence; PEF = peak expiratory flow; PFT = pulmonary function test; QOL = quality of life; RQLQ = Rhinoconjunctivitis Quality of Life Questionnaire; SCIT = subcutaneous immunotherapy.

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.